FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
Portfolio Pulse from Vandana Singh
The FDA has approved Epkinly, a T-cell engaging bispecific antibody for adult patients with relapsed or refractory diffuse large B-cell lymphoma, co-developed and co-commercialized by Genmab A/S (GMAB) and AbbVie Inc (ABBV). The drug demonstrated a 61% overall response rate and 38% complete remission in a Phase 2 study.
May 19, 2023 | 5:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's Epkinly, co-developed with Genmab, receives FDA approval as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
The FDA approval of Epkinly is a significant milestone for AbbVie, as it expands the company's product portfolio and strengthens its position in the oncology market. The positive results from the Phase 2 study indicate the drug's potential to address a challenging patient population, which could lead to increased demand and revenue for AbbVie. This news is likely to have a positive short-term impact on ABBV's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 50
POSITIVE IMPACT
Genmab's Epkinly, co-developed with AbbVie, receives FDA approval as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
The FDA approval of Epkinly is a significant milestone for Genmab, as it expands the company's product portfolio and strengthens its position in the oncology market. The positive results from the Phase 2 study indicate the drug's potential to address a challenging patient population, which could lead to increased demand and revenue for Genmab. This news is likely to have a positive short-term impact on GMAB's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 50